NEO/ONCO (NEO/ONCO)

Cboe Canada: NEO/ONCO · CAD

CA$0.27

-0.01 (-3.6%)· Recorded snapshot

Market cap	18.7M
Revenue (ttm)	90.9K
Net income (ttm)	-11.5M
EPS (ttm)	-CA$0.20
Shares out	69.2M
Volume	2,000

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 90.9K
Net income (ttm): -11.5M
EPS (ttm): -CA$0.20
Market cap: 18.7M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-592.6

P25 n/aP50 n/aP75 n/a

ROIC-257.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NEO/ONCO indicators

Market & fundamental data

Available fields

142

Groups with data

Currency

CAD

Showing 142 of 142 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	CAD
Country	Canada
Country code	CA
Earnings date	2026-12-15
Enterprise value	CAD 18.9M
Exchange	Cboe Canada
Financial currency	CAD
Financial report date	2026-07-31
First seen	2026-05-10
Fiscal year end	April
Industry	Biotechnology
Is primary listing	Yes
ISIN number	CA68237C1059
Last earnings date	2025-12-12
Last refreshed	2026-10-29
Market cap	CAD 18.7M
Next earnings date	2026-12-15
Price	CAD 0.27
Price currency	CAD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-29
Symbol	neo/ONCO
Website	https://oncoinnovations.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-74.13%
EV/Sales	215.12x
FCF / EV yield	-26.95%
FCF yield	-27.18%
P/B ratio	6.84x
P/S ratio	213.28x
Price / tangible book value	6.84x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-9,431.98%
Pretax margin	-12,625.19%
ROA	-176.77%
ROCE	-302.49%
ROE	-592.62%
ROIC	-257.94%
SBC / revenue	5,834.46%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Gross profit growth	7.18%
Revenue growth	7.18%

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	CAD -8.6M
EPS	CAD -0.20
FCF per share	CAD -0.08
Financing cash flow	CAD 3.2M
Free cash flow	CAD -5.3M
Free cash flow minus SBC	CAD -10.6M
Gross profit	CAD 90,878
Net borrowing	CAD 280,000
Net cash flow	CAD -828,875
Net income	CAD -11.5M
Operating cash flow minus SBC	CAD -9.4M
Operating income	CAD -8.6M
Revenue	CAD 90,878
Stock-based compensation	CAD 5.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	11.84
Book value per share	CAD 0.04
Debt / equity	0.1
Interest coverage	-5,096.08
Long-term assets	CAD 1.3M
Long-term liabilities	CAD 0
Net cash (debt)	CAD -167,297
Net cash / market cap	-0.86%
Net debt / equity	0.06
Piotroski F-Score	1
Shareholders' equity	CAD 2.8M
Tangible book value	CAD 2.8M
Tangible book value per share	CAD 0.04
Total assets	CAD 4.5M
Total cash	CAD 114,385
Total debt	CAD 281,682
Total liabilities	CAD 1.7M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.03
Current assets	CAD 3.2M
Current liabilities	CAD 1.7M
Current ratio	1.89
Net working capital	CAD 1.7M
Quick ratio	1.65
Working capital	CAD 1.5M
Working capital turnover	0.07

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-25.92%
Dividend per share	CAD 0.00
Last dividend	CAD 0.00
Shareholder yield	-25.92%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	CAD 0.68
1D price change	-3.57%
1M price change	-32.5%
1M total return	-32.5%
1W price change	17.39%
1W total return	17.39%
1Y price change	-80.71%
1Y return CAGR	-80.74%
1Y total return	-80.71%
20-day SMA	CAD 0.30
200-day SMA	CAD 0.71
3M price change	-61.43%
3M total return	-61.43%
50-day SMA	CAD 0.41
50-day SMA vs 200-day SMA	50under200
52-week high	CAD 1.83
52-week high date	2025-11-24
52-week low	CAD 0.22
52-week low date	2026-10-27
6M price change	-76.52%
6M total return	-76.52%
All-time high	CAD 2.80
All-time high date	2025-02-25
All-time low	CAD 0.22
All-time low date	2026-10-22
Average true range (ATR)	CAD 0.04
Average volume	61.6K
Beta (1Y)	0.79
Beta (2Y)	1.07
Change from 52-week high	-85.25%
Change from 52-week low	22.73%
Change from all-time high	-90.36%
Change from all-time low	22.73%
Change from open	0%
Day's gap	-3.57%
Dollar volume	CAD 540
High price	CAD 0.27
Low price	CAD 0.27
Monthly RSI	41.34
Open price	CAD 0.27
Previous close	CAD 0.28
Price vs 150-day SMA	-60.51%
Price vs 20-day SMA	-9.7%
Price vs 200-day SMA	-62.19%
Price vs 50-day SMA	-33.61%
Relative volume	0.03
RSI	40.29
Sharpe ratio	-0.94
Sortino ratio	-1.29
Volume	2K
Weekly RSI	30.41
YTD price change	-80%
YTD total return	-80%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	66.7M
Shares change (QoQ)	2.34%
Shares change (YoY)	25.92%
Shares held by insiders	2.5%
Shares outstanding	69.2M

Deeper analysis on NEO/ONCO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NEO/ONCO report

Is a complete NEO/ONCO research report available?

No complete published report is available for neo/ONCO (NEO/ONCO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NEO/ONCO (NEO/ONCO)

Price

Financial snapshot

Fair-value bridge

Latest news · NEO/ONCO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NEO/ONCO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NEO/ONCO

Frequently asked questions